Effect of expansile paclitaxel-loaded nanoparticles on growth of lung cancer in vivo

• DOI: 10.1200/jco.2008.26.15_suppl.7593
• Publication Date: 2017-02-24T07:33:44Z
• Authors: J. Walpole; A. Griset; A. Gaffey; M. W. Grinstaff; Y. Colson
• Keywords: Lewis lung carcinoma

7593 Background: Surgical resection remains the most effective treatment for patients with non-small cell lung cancer; however, even in early stage diagnoses presence of occult microscopic disease at surgical margin significantly impacts long-term patient survival. Thus, focus this study is to establish proof concept that locoregional growth tumor burden can be prevented through application a novel “expansile” nanoparticle drug delivery system. Methods: Biocompatible polymer nanoparticles enter cells and swell 300 fold response pH were loaded paclitaxel (Pax-NP) assessed efficacy against murine Lewis carcinoma (LLC) using viability assays vitro implantation vivo. Paclitaxel-loaded non-expansile (Pax-neNP) are not sensitive variation also produced. For vivo studies, 7.5 x 105 LLC co-injected 0.25 mg unloaded control (expansile) NP, Pax-NP, Pax-neNP or alone 100μL Cremophor EL/ethanol (each equivalent 2.5 μg dose paclitaxel) subcutaneously C57Bl/6 mice. Results: In demonstrated co-culture Pax-NP results significant inhibition (p<0.01, t-test vs control). contrast, incubated NP did inhibit growth. Moreover, Whereas (n=11) 0.25mg (n=14) (n=12) resulted development tumors volumes 388±86, 382±82 268±63 mm3, respectively (mean ± SE), only one mouse (n=15) developed small (2±2 mm3) following injection (p<0.05 via ANOVA). Further, an reduce (225±95, n=6). Conclusions: These inhibited by intracellular nanoparticle-mediated delivery. suggest which undergo cellular uptake resultant release, may afford enhanced local aimed preventing present parenchyma-sparing surgery cancer. No financial relationships disclose.